Teva Pharmaceutical Industries Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard Francis
- Full Time Employees
- 33,346
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- 124 Dvora Hanevi’a Street Tel Aviv TA Israel 6944020
- IPO Date
- Jan 1, 1951
- Website
- tevapharm.com
- Similar Companies
- Business
- Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited develops, manufactures, markets and distributes generic medicines, innovative and specialty biopharmaceutical products worldwide. The company offers a broad portfolio of generic medicines in various dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams; sterile products, hormones, high-potency drugs and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Its key branded products comprise Austedo (deutetrabenazine) for chorea associated with Huntington's disease and tardive dyskinesia; Ajovy (fremanezumab) for preventive migraine treatment in adults; Copaxone for relapsing forms of multiple sclerosis; and Bendeka and Treanda injections for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, alongside active pharmaceutical ingredients and over-the-counter offerings. Teva operates in the United States, Europe, Israel and internationally, with manufacturing facilities across North America, Europe, Australia, South America and Israel; it maintains headquarters in Petah Tikva, Israel, tracing origins to predecessors founded in 1901 and incorporating as Teva in 1935. Recent developments include increased 2025 revenue outlook for Austedo and non-GAAP EPS following third-quarter 2025 results showing $4.5 billion in revenues up 3% year-over-year; a strategic partnership announced in February 2024 with Jiangsu Nhwa Hexin for Austedo marketing and distribution in China; and presentation of positive Phase 2b study results for duvakitug (anti-TL1A) in collaboration with Sanofi at ECCO 2025, alongside heightened R&D investments in immunology, immuno-oncology and neuroscience pipelines.
Company News
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 Earnings Call Transcript
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Q3 profit gain beats estimates
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Why Is Teva Stock Trading Lower on Monday?
Teva to discontinue mid-stage neurodegenerative disorder study
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More
Teva: I Still See Upside After A Massive Rally
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript